Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 NWPsXXltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LxOGlEPTB;MD6wNFAzQDdizszN MUHTRW5ITVJ?
LC-2-ad MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMECwN|E4KM7:TR?= Mm\SV2FPT0WU
RL95-2 M4rHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vzWmlEPTB;MD6wNFA3PjhizszN NYDDSmNkW0GQR1XS
MZ1-PC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;CUnBmUUN3ME2wMlAxODd{OTFOwG0> NUPKfYUxW0GQR1XS
TE-8 M3nrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTFcHB1UUN3ME2wMlAxOTF5IN88US=> NX\YOId{W0GQR1XS
SW954 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXOVXRKSzVyPUCuNFAyOTlizszN M1fKPXNCVkeHUh?=
TE-11 NUC2UFV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW3TWM2OD1yLkCwNVI{KM7:TR?= NVHj[4tTW0GQR1XS
PSN1 NYPEOVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XwbGlEPTB;MD6wNFE{KM7:TR?= MXnTRW5ITVJ?
MOLT-4 NHHSSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HvW2lEPTB;MD6wNFE1QSEQvF2= MWPTRW5ITVJ?
697 NYLHXVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMECxOUDPxE1? NX7ET45NW0GQR1XS
ETK-1 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILadJBKSzVyPUCuNFAyPTJizszN MWrTRW5ITVJ?
TE-10 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PVOGlEPTB;MD6wNFE2PCEQvF2= NXe1XIMyW0GQR1XS
HUTU-80 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMECxOlgh|ryP NYHpZ4xCW0GQR1XS
NTERA-S-cl-D1 NYLTNW9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDkfHh[UUN3ME2wMlAxOjB7IN88US=> M{TF[nNCVkeHUh?=
MFH-ino MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMECyOlgh|ryP NWXGcXRtW0GQR1XS
IA-LM NFmwXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GxXWlEPTB;MD6wNFI5KM7:TR?= MXHTRW5ITVJ?
MC116 NIfaOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17xNmlEPTB;MD6wNFI5QSEQvF2= M3S4OHNCVkeHUh?=
RKO NXTPb4hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\4WXNKSzVyPUCuNFAzQThizszN MXHTRW5ITVJ?
MRK-nu-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonqTWM2OD1yLkCwNlk6KM7:TR?= MoraV2FPT0WU
VA-ES-BJ MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMECzJO69VQ>? MVTTRW5ITVJ?
KALS-1 NEDUT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\NTWM2OD1yLkCwN|A5KM7:TR?= NEHvS3pUSU6JRWK=
BB30-HNC NWP6RVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljGTWM2OD1yLkCwN|E1KM7:TR?= NHzTfXdUSU6JRWK=
ACN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zySmlEPTB;MD6wNFMyPiEQvF2= M2LuW3NCVkeHUh?=
TE-9 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMECzNlYh|ryP MY\TRW5ITVJ?
SIG-M5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7KXpZ{UUN3ME2wMlAxOzJ5IN88US=> MXrTRW5ITVJ?
no-10 NXvDepVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH5RYVKSzVyPUCuNFA{PjJizszN NYW1enFjW0GQR1XS
EW-1 NI\UVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMECzO|Eh|ryP M12xc3NCVkeHUh?=
SK-LMS-1 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TsRmlEPTB;MD6wNFQxOSEQvF2= MkLKV2FPT0WU
GT3TKB MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\CTGlEPTB;MD6wNFQ{PCEQvF2= NXzZXGIxW0GQR1XS
ES4 NIOweGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnVZphqUUN3ME2wMlAxPDR7IN88US=> NGjkbZFUSU6JRWK=
IMR-5 M4\2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfHTWM2OD1yLkCwOFUh|ryP NX7jR2ZWW0GQR1XS
NCI-H1648 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMEC0Olkh|ryP M1npSnNCVkeHUh?=
MV-4-11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTPXmN[UUN3ME2wMlAxPDd3IN88US=> MXfTRW5ITVJ?
SK-UT-1 M1\WSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnMV5lFUUN3ME2wMlAxPDhizszN MnHYV2FPT0WU
NB13 NUDZZpFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7SXYxiUUN3ME2wMlAxPDlzIN88US=> MkfqV2FPT0WU
DJM-1 NFrKR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHyfYxwUUN3ME2wMlAxPTNizszN M3XVPXNCVkeHUh?=
ES8 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HpUGlEPTB;MD6wNFU{QCEQvF2= NVe2d40zW0GQR1XS
TE-6 M2G1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEC1O{DPxE1? NYXKc3h3W0GQR1XS
KS-1 NEnyTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfETIdQUUN3ME2wMlAxPTh{IN88US=> M2faPHNCVkeHUh?=
TE-1 NIrq[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD0TWM2OD1yLkCwOlA3KM7:TR?= M{HZe3NCVkeHUh?=
ATN-1 NGnvN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHTWZdKSzVyPUCuNFA3ODlizszN MmTRV2FPT0WU
A4-Fuk Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEC2NVEh|ryP NGHyfYxUSU6JRWK=
ALL-PO NHHFbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPRTWM2OD1yLkCwOlMh|ryP M2rWNnNCVkeHUh?=
BE-13 M3nRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[2cGFPUUN3ME2wMlAxPjN4IN88US=> M4jJ[3NCVkeHUh?=
KM12 M4[0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;wPXdKSzVyPUCuNFA3OzdizszN MlLwV2FPT0WU
NOS-1 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33BcGlEPTB;MD6wNFY2KM7:TR?= NWHBb4tVW0GQR1XS
SW962 NUjsV|NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInNbmpKSzVyPUCuNFA3PjJizszN Mke3V2FPT0WU
OCUB-M NIC5fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3TUoZKSzVyPUCuNFA3PjJizszN MV\TRW5ITVJ?
NCI-H510A NFzVcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jZcmlEPTB;MD6wNFY3PSEQvF2= NFHDdpdUSU6JRWK=
EW-16 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjoTWM2OD1yLkCwOlk1KM7:TR?= M{DJZnNCVkeHUh?=
KGN NWr4SplGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInJUGlKSzVyPUCuNFA4OTJizszN NXvjdIdPW0GQR1XS
LS-411N M2ezUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DXXGlEPTB;MD6wNFcyPyEQvF2= NGnV[49USU6JRWK=
Becker NX7ZcFdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMEC3NkDPxE1? MVfTRW5ITVJ?
HC-1 NYfVRZNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fR[2lEPTB;MD6wNFczOSEQvF2= M3\6T3NCVkeHUh?=
CESS Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rl[mlEPTB;MD6wNFc{PyEQvF2= M1nJXHNCVkeHUh?=
KURAMOCHI NFfTUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEC3OFgh|ryP NGi0XXFUSU6JRWK=
TGBC24TKB MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi2TWM2OD1yLkCwO|UzKM7:TR?= MX3TRW5ITVJ?
SW982 NXTEV|dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjxPWlKSzVyPUCuNFA4PjZizszN NWr1N|A2W0GQR1XS
HCE-4 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOyNXJKSzVyPUCuNFA4PjdizszN NHXSNIRUSU6JRWK=
LOUCY NFfEWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn61TWM2OD1yLkCwO|c2KM7:TR?= NGrPOJZUSU6JRWK=
8-MG-BA MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEC3PVYh|ryP NHj5XZlUSU6JRWK=
HT-144 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfCdZY3UUN3ME2wMlAxQCEQvF2= M4\YPXNCVkeHUh?=
LXF-289 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDIbIxWUUN3ME2wMlAxQDF6IN88US=> M3jMZ3NCVkeHUh?=
RS4-11 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:5Z|Y6UUN3ME2wMlAxQDN4IN88US=> MmPmV2FPT0WU
DEL MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3STWM2OD1yLkCwPFQ2KM7:TR?= Mn\NV2FPT0WU
OCI-AML2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nvUmlEPTB;MD6wNFg2OiEQvF2= MUPTRW5ITVJ?
CCRF-CEM NEHQfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3oPHFKSzVyPUCuNFA5PzFizszN M4qwOHNCVkeHUh?=
A388 NXL2SldCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnpT3ZKSzVyPUCuNFA5PzRizszN NEPOeo9USU6JRWK=
KNS-42 MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMEC4PVEh|ryP MmX0V2FPT0WU
OVCAR-4 M3:2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy2VWxlUUN3ME2wMlAxQTB2IN88US=> M1Lmc3NCVkeHUh?=
NCI-H1355 NX\ydVA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMEC5NVQh|ryP NEDXclJUSU6JRWK=
BL-70 NHrUSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEC5N{DPxE1? NET2U4NUSU6JRWK=
BL-41 NGH3N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\aTWM2OD1yLkCwPVM1KM7:TR?= NWTCSnc6W0GQR1XS
A101D M3viWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zZdWlEPTB;MD6wNFk3KM7:TR?= M{i5XnNCVkeHUh?=
HL-60 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTuTWM2OD1yLkCwPVY3KM7:TR?= MWHTRW5ITVJ?
COR-L279 NG[3d4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rEW2lEPTB;MD6wNFk6QSEQvF2= Ml;PV2FPT0WU
NCI-SNU-16 NEmwRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH2R4hNUUN3ME2wMlAyODB6IN88US=> MnTHV2FPT0WU
Calu-6 M1nHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj2[GtvUUN3ME2wMlAyODF{IN88US=> MVTTRW5ITVJ?
SR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEGwNlYh|ryP M374NHNCVkeHUh?=
QIMR-WIL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\Rc5VKSzVyPUCuNFExOzNizszN NVG0WIFzW0GQR1XS
LB647-SCLC NFPIZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DvbGlEPTB;MD6wNVA2OSEQvF2= MnnOV2FPT0WU
RPMI-8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HR[2lEPTB;MD6wNVExOiEQvF2= NUDocnkyW0GQR1XS
SK-PN-DW MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTGb2RJUUN3ME2wMlAyOTF{IN88US=> NF\mbmVUSU6JRWK=
SF268 NV:yd3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljwTWM2OD1yLkCxNVUyKM7:TR?= MorhV2FPT0WU
HD-MY-Z Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\UU2ZKSzVyPUCuNFEyPjNizszN MoS4V2FPT0WU
DOHH-2 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fMTWlEPTB;MD6wNVIxOyEQvF2= MVLTRW5ITVJ?
SCC-3 NYTwRW5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv5SmhKSzVyPUCuNFEzODRizszN MoP5V2FPT0WU
ST486 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi2doVKSzVyPUCuNFEzODRizszN NEnWfpJUSU6JRWK=
NALM-6 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT0TWM2OD1yLkCxNlE1KM7:TR?= NEDaXZlUSU6JRWK=
NCI-H1436 MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz5TGJKUUN3ME2wMlAyOjNzIN88US=> MlzPV2FPT0WU
KE-37 NYnqOmk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\zOmlEPTB;MD6wNVI{PCEQvF2= NIm2NIVUSU6JRWK=
RPMI-8402 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEGyOVYh|ryP M1PQWXNCVkeHUh?=
RXF393 NVzXbllLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\GTWM2OD1yLkCxNlU4KM7:TR?= MonTV2FPT0WU
KARPAS-45 NVHiWZVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfxNGk1UUN3ME2wMlAyOjdizszN MUjTRW5ITVJ?
HOP-62 NILFToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDnZlVKSzVyPUCuNFEzPzZizszN NWraVnM3W0GQR1XS
ES1 NF3Q[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXiwNXZlUUN3ME2wMlAyOjh6IN88US=> M{P4O3NCVkeHUh?=
L-363 NVfkWGFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnYclRKSzVyPUCuNFE{PTFizszN NHLQOXNUSU6JRWK=
GI-1 M3vG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17NSGlEPTB;MD6wNVM4OyEQvF2= MVzTRW5ITVJ?
CTV-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfxb2hKSzVyPUCuNFE1PzhizszN NGDOTGxUSU6JRWK=
TE-5 NUPvS45PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEG0PVYh|ryP M4TkfXNCVkeHUh?=
SNU-C2B NHLBNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn35TWM2OD1yLkCxOFk3KM7:TR?= NF7RZ3lUSU6JRWK=
K-562 NEC0ZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W5WmlEPTB;MD6wNVUyPiEQvF2= MofHV2FPT0WU
SNB75 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPUTFJKSzVyPUCuNFE2PCEQvF2= NGLhfJRUSU6JRWK=
MOLT-13 MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vu[mlEPTB;MD6wNVY{PyEQvF2= NVTYd2IyW0GQR1XS
LS-123 NYjyXlVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[5fGlEPTB;MD6wNVY3PCEQvF2= NFGzVXhUSU6JRWK=
NCI-SNU-5 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\QTWM2OD1yLkCxO|AyKM7:TR?= M{\iVHNCVkeHUh?=
Daudi NWWycXpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;yemlEPTB;MD6wNVcxQCEQvF2= NXO0Sm5CW0GQR1XS
A253 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\2cW5rUUN3ME2wMlAyPzN6IN88US=> M4jUTXNCVkeHUh?=
TGBC1TKB NX;nXW51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLXRpdKSzVyPUCuNFE4PTJizszN NFfDOJBUSU6JRWK=
SJSA-1 NFHrVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXGTWM2OD1yLkCxO|Y4KM7:TR?= NYfr[XRqW0GQR1XS
NCCIT M3:3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O0eWlEPTB;MD6wNVc3QSEQvF2= MVzTRW5ITVJ?
NCI-H69 M1;INWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEG3O|gh|ryP NXSzSoc{W0GQR1XS
SH-4 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{WxUmlEPTB;MD6wNVg6PSEQvF2= M2LoVHNCVkeHUh?=
HCC1187 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnQTWM2OD1yLkCxPVI1KM7:TR?= M2\H[nNCVkeHUh?=
HCC1599 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HpbmlEPTB;MD6wNlAzKM7:TR?= MmPrV2FPT0WU
ONS-76 NGD1RWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTwb2ZKSzVyPUCuNFIxOzZizszN NEnLT4xUSU6JRWK=
KU812 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEKwN|kh|ryP NYfydpBzW0GQR1XS
ML-2 NILob2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e2UGlEPTB;MD6wNlA1PyEQvF2= MYLTRW5ITVJ?
HCE-T NX7SW4xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rpc2lEPTB;MD6wNlA6OiEQvF2= MoWzV2FPT0WU
NCI-H446 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTSN3lqUUN3ME2wMlAzOTF{IN88US=> MlO2V2FPT0WU
RPMI-6666 M1vUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XCcmlEPTB;MD6wNlE1QSEQvF2= M3vjfXNCVkeHUh?=
MOLT-16 NV;DdJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTxTWM2OD1yLkCyNVU{KM7:TR?= MnrnV2FPT0WU
JiyoyeP-2003 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEKxO|Yh|ryP Mnr4V2FPT0WU
MHH-PREB-1 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEKxPVEh|ryP MYXTRW5ITVJ?
MC-CAR NIC5N3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG5TWM2OD1yLkCyN|I3KM7:TR?= MY\TRW5ITVJ?
BC-3 M{TsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXZdGlKSzVyPUCuNFI{PDRizszN Ml\PV2FPT0WU
KINGS-1 NVjPeVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rxbWlEPTB;MD6wNlM2PSEQvF2= Ml3mV2FPT0WU
PF-382 M1f2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XCUWlEPTB;MD6wNlM4QCEQvF2= NXzxbHR{W0GQR1XS
J-RT3-T3-5 NFyxXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MormTWM2OD1yLkCyN|g{KM7:TR?= NEG1RWNUSU6JRWK=
SF539 NGrVVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\0WFduUUN3ME2wMlAzPDBzIN88US=> M3fXUHNCVkeHUh?=
LB831-BLC MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nWWWlEPTB;MD6wNlQ5PSEQvF2= MV;TRW5ITVJ?
DMS-114 NILuWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEK1NFIh|ryP MmDTV2FPT0WU
LB1047-RCC M3v4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEK1NUDPxE1? NIjUOmhUSU6JRWK=
LB771-HNC NXnaOm1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nLUWlEPTB;MD6wNlU{PCEQvF2= MnrJV2FPT0WU
BB65-RCC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTjPW5KSzVyPUCuNFI2OzRizszN NEL5V49USU6JRWK=
BV-173 M1;2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\XZWlEPTB;MD6wNlU2PCEQvF2= M2\RNHNCVkeHUh?=
ARH-77 M2LpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\mTWM2OD1yLkCyOlAyKM7:TR?= NWDmO|VCW0GQR1XS
IST-MEL1 NFfINpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEK2NlMh|ryP MnXFV2FPT0WU
NB1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLyTG1KSzVyPUCuNFI3QDdizszN NYnLOoMxW0GQR1XS
EoL-1-cell MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXMPFdKSzVyPUCuNFI3QDhizszN MUTTRW5ITVJ?
KY821 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEK2PVch|ryP M1uycHNCVkeHUh?=
CMK NVHMOGJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrUcmNKSzVyPUCuNFI4OzRizszN NHLCZXhUSU6JRWK=
NCI-H2126 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[3NGlEPTB;MD6wNlc3QCEQvF2= NEjScphUSU6JRWK=
NCI-H526 M3r5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPMTWM2OD1yLkCyPFkyKM7:TR?= NWP1cGFxW0GQR1XS
COLO-684 M2riZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXGTWM2OD1yLkCyPVA5KM7:TR?= NYm4Zpk3W0GQR1XS
NCI-H747 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEK5N|Mh|ryP NXrhbYVWW0GQR1XS
JAR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fMOWlEPTB;MD6wNlk1PiEQvF2= M4TF[3NCVkeHUh?=
MEG-01 NWLsV4ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXOVpdKSzVyPUCuNFI6PzhizszN MVPTRW5ITVJ?
MONO-MAC-6 M2\QPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTmbYRVUUN3ME2wMlA{ODJ|IN88US=> NF7jSpdUSU6JRWK=
IST-SL1 NHvXRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW5eYFMUUN3ME2wMlA{ODR{IN88US=> MmTUV2FPT0WU
CPC-N NGe1SG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPLTW9KSzVyPUCuNFMxPzlizszN MWLTRW5ITVJ?
NCI-H1963 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLqTWM2OD1yLkCzNVMyKM7:TR?= MVXTRW5ITVJ?
K052 Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3UZXR1UUN3ME2wMlA{OjR5IN88US=> MnqyV2FPT0WU
KM-H2 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTtTWM2OD1yLkCzN|A4KM7:TR?= NHrvWGpUSU6JRWK=
TE-12 M4T6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEOzNFkh|ryP NEHTTZlUSU6JRWK=
TK10 NVmwcGRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDyTWM2OD1yLkCzN|U3KM7:TR?= M3\ERXNCVkeHUh?=
NMC-G1 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\2WodKSzVyPUCuNFM1PTJizszN NYjQXIxTW0GQR1XS
no-11 NV3WNGpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;BTWM2OD1yLkCzOFc5KM7:TR?= M{e2THNCVkeHUh?=
NCI-H524 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PjNWlEPTB;MD6wN|UzQSEQvF2= NUDZTHpCW0GQR1XS
MHH-CALL-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rZWmlEPTB;MD6wN|U3OiEQvF2= NYO4S|lOW0GQR1XS
GB-1 M33pUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j4cmlEPTB;MD6wN|Yh|ryP MXXTRW5ITVJ?
OPM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\rfJo5UUN3ME2wMlA{Pjd|IN88US=> NIWyR3RUSU6JRWK=
RH-1 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHGcXRHUUN3ME2wMlA{QDF7IN88US=> NX;vfY5JW0GQR1XS
NCI-H64 M3OxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2flZ2lEPTB;MD6wN|g2PyEQvF2= MnPHV2FPT0WU
EVSA-T MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEO5NlMh|ryP MUHTRW5ITVJ?
KARPAS-299 M3f0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzaTWM2OD1yLkCzPVgh|ryP MUfTRW5ITVJ?
MZ7-mel M2[1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfIS|hHUUN3ME2wMlA1ODRizszN MXvTRW5ITVJ?
LB373-MEL-D NEPBZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\H[mlEPTB;MD6wOFExPSEQvF2= M3jXSHNCVkeHUh?=
HEL M120Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnntTWM2OD1yLkC0NVQh|ryP MX7TRW5ITVJ?
SW872 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrEVJpKSzVyPUCuNFQzOSEQvF2= MmHwV2FPT0WU
DU-4475 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nVfmlEPTB;MD6wOFI1PCEQvF2= NFfWV4xUSU6JRWK=
IST-SL2 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMESyO|Uh|ryP MlLxV2FPT0WU
NCI-H82 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzPdXdKSzVyPUCuNFQ{ODdizszN M1XMfXNCVkeHUh?=
LC4-1 M1;aTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\PeoZKSzVyPUCuNFQ{PTFizszN NEHNbG9USU6JRWK=
HDLM-2 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfIWnliUUN3ME2wMlA1Ozl{IN88US=> NETVdGNUSU6JRWK=
MMAC-SF NIfQfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMES1N|Qh|ryP NFjRPWNUSU6JRWK=
L-540 NYrYRnQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHVTWM2OD1yLkC0OlM6KM7:TR?= MWTTRW5ITVJ?
MZ2-MEL NFr3SIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDrNGRpUUN3ME2wMlA1PzR{IN88US=> Ml3LV2FPT0WU
LU-134-A M4qycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfi[mlKSzVyPUCuNFQ4PzNizszN M4LXWnNCVkeHUh?=
UACC-257 NXjYV2ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP5TWM2OD1yLkC0PFQ6KM7:TR?= MUjTRW5ITVJ?
NCI-H1581 NGrqWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGzW4E6UUN3ME2wMlA1QTV|IN88US=> MkmxV2FPT0WU
NB17 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPYbFFKSzVyPUCuNFQ6PzlizszN NFm3d3VUSU6JRWK=
SBC-1 NIDEN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXwXFVKSzVyPUCuNFUxPDJizszN MY\TRW5ITVJ?
TALL-1 NVvMfGk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;mT41KSzVyPUCuNFUxPDVizszN NW\m[VNoW0GQR1XS
NCI-H1304 NEDDcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEWyNFgh|ryP M2K4ZXNCVkeHUh?=
NEC8 NXLF[GZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTzb3JKSzVyPUCuNFUzQDZizszN M37KZ3NCVkeHUh?=
CAL-148 NIqyO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMEW0N|kh|ryP NIrQbWtUSU6JRWK=
CGTH-W-1 NVyydI5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;hPGlEPTB;MD6wOVQ1QSEQvF2= NUTYTG5qW0GQR1XS
NCI-H889 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTSXWViUUN3ME2wMlA2PTl{IN88US=> NIrveIxUSU6JRWK=
GR-ST NVP5bnNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XucWlEPTB;MD6wOVYzOSEQvF2= NXTrTW9zW0GQR1XS
KARPAS-422 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMEW2OUDPxE1? NEG5bpRUSU6JRWK=
RPMI-8866 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DrdGlEPTB;MD6wOVcyOiEQvF2= M3fscHNCVkeHUh?=
SCLC-21H NHH3OpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\LTWM2OD1yLkC1PFg1KM7:TR?= NHSwSHVUSU6JRWK=
COR-L88 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfB[|gzUUN3ME2wMlA2QTJ5IN88US=> NIrwNY9USU6JRWK=
LU-139 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDOc5JKSzVyPUCuNFU6QDZizszN NH\EVJRUSU6JRWK=
SF126 M2XLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7sNmFKSzVyPUCuNFYyOzNizszN Mln4V2FPT0WU
NCI-H1882 NGmz[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXFbJlKSzVyPUCuNFY1OjRizszN NHz3bXZUSU6JRWK=
EW-24 NYnQWJF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:zTWM2OD1yLkC2OFg{KM7:TR?= M{jBR3NCVkeHUh?=
CP67-MEL NEm3S5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzrTWM2OD1yLkC2PFEh|ryP MlrZV2FPT0WU
DG-75 NX23PYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDVpNKSzVyPUCuNFY5QTlizszN MYHTRW5ITVJ?
LOXIMVI MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X6SGlEPTB;MD6wO|AzQCEQvF2= MYDTRW5ITVJ?
HH M{n3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnBNWRKSzVyPUCuNFcyPTdizszN NFjq[GFUSU6JRWK=
K5 NVjzUpBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HuVmlEPTB;MD6wO|IzPiEQvF2= NXy2emx{W0GQR1XS
EC-GI-10 NEjSbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEeyOVch|ryP NGTZemlUSU6JRWK=
SK-N-DZ MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHXc2NKSzVyPUCuNFc{ODdizszN NHv3OHNUSU6JRWK=
A3-KAW MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEezOVEh|ryP NXjyWWQ2W0GQR1XS
MLMA MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K2OmlEPTB;MD6wO|Q3PSEQvF2= M1\EfXNCVkeHUh?=
LB996-RCC MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml33TWM2OD1yLkC3O|A4KM7:TR?= NXm4bI8zW0GQR1XS
OS-RC-2 M162Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEe3OFgh|ryP MXHTRW5ITVJ?
CTB-1 NGDsVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\GZnZKSzVyPUCuNFc5OSEQvF2= MUTTRW5ITVJ?
IST-MES1 NYn3[G5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DwUWlEPTB;MD6wO|kyOiEQvF2= Mm\4V2FPT0WU
LS-1034 M2S5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jZZWlEPTB;MD6wPFA{PSEQvF2= NHy3fGpUSU6JRWK=
HT MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEiwPFYh|ryP MYrTRW5ITVJ?
NCI-H2141 NVXmTWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jnNmlEPTB;MD6wPFEh|ryP NE\pNXNUSU6JRWK=
LB2518-MEL NE\LdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzrNHhKSzVyPUCuNFgyPDFizszN MX3TRW5ITVJ?
GI-ME-N NHrWOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMEi0OVIh|ryP MnPoV2FPT0WU
TGW NUmybo5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17BSmlEPTB;MD6wPFYxPyEQvF2= NYLXdHVNW0GQR1XS
SK-NEP-1 NYPKTWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMEi2OFEh|ryP MkDlV2FPT0WU
NOMO-1 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHoNIdEUUN3ME2wMlA6Ojd3IN88US=> MWTTRW5ITVJ?
ES6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjlNY5KSzVyPUCuNFk2QDlizszN NWruV4dVW0GQR1XS
NCI-H209 NVqxc4xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nEVmlEPTB;MD6wPVc5PiEQvF2= MVLTRW5ITVJ?
GAK Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHie4Z1UUN3ME2wMlExOTZizszN NIW0bWRUSU6JRWK=
BC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPuV4hsUUN3ME2wMlExOzZzIN88US=> M{nKVXNCVkeHUh?=
KLE MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn0TWM2OD1yLkGwOFQ{KM7:TR?= Ml3EV2FPT0WU
EW-3 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH33NJZKSzVyPUCuNVA6QCEQvF2= MYnTRW5ITVJ?
NKM-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMUGxJO69VQ>? MVzTRW5ITVJ?
D-336MG M2HXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[4TmlEPTB;MD6xNVI1PCEQvF2= NECxWWtUSU6JRWK=
NB69 NYW5flBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDZ4FKSzVyPUCuNVE{ODFizszN NWnsdppxW0GQR1XS
D-263MG NXjOO2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TmcGlEPTB;MD6xNVcyOiEQvF2= MofCV2FPT0WU
KP-N-YS M174[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXBdYo4UUN3ME2wMlEzOjlzIN88US=> M33pWHNCVkeHUh?=
NCI-H1155 NXq2Nlg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2w[5RTUUN3ME2wMlEzPTV6IN88US=> NH[ye2VUSU6JRWK=
BOKU NXHBOWg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi1bGNKSzVyPUCuNVI2PzlizszN NHK1VWlUSU6JRWK=
LAMA-84 NE\qVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT4c5ZKSzVyPUCuNVI6QSEQvF2= M2XyTnNCVkeHUh?=
Raji MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMUOxNVch|ryP M3LMRnNCVkeHUh?=
LU-65 Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn4[m1IUUN3ME2wMlE{OzB5IN88US=> M{\jR3NCVkeHUh?=
NCI-H187 NIHhdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrHPIFtUUN3ME2wMlE{QTJ2IN88US=> MVPTRW5ITVJ?
GCIY MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HtZ2lEPTB;MD6xOFkxOSEQvF2= MkjNV2FPT0WU
NCI-H2107 M17DcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXsXHFKSzVyPUCuNVUxQCEQvF2= MULTRW5ITVJ?
NCI-H1522 NHjPXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMUWyOlYh|ryP MUnTRW5ITVJ?
NB6 NFzZWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LKcmlEPTB;MD6xOVYzOyEQvF2= NHz1blRUSU6JRWK=
EM-2 NGj1NIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjRdGE2UUN3ME2wMlE2PzB4IN88US=> MoOwV2FPT0WU
HCC2218 M4rSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMUW5PEDPxE1? Mn\wV2FPT0WU
NCI-H748 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWw[XlTUUN3ME2wMlE3Ozd4IN88US=> NFzjUJpUSU6JRWK=
MS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TW[mlEPTB;MD6xOlU{PyEQvF2= NXzVXo9oW0GQR1XS
NB5 NEHJUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLYd3Q3UUN3ME2wMlE3PTl5IN88US=> NVLUUHF{W0GQR1XS
OMC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOyXVJoUUN3ME2wMlE3Pjh6IN88US=> MXXTRW5ITVJ?
NCI-H345 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL5TWM2OD1yLkG2PVI5KM7:TR?= NH2zTZhUSU6JRWK=
L-428 NHTlSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHTcZBKSzVyPUCuNVY6PDVizszN MYXTRW5ITVJ?
SCH MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;6cWlEPTB;MD6xPFY5PSEQvF2= Ml\mV2FPT0WU
NCI-H1417 NUTiR5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHtT5lWUUN3ME2wMlE6OjJ5IN88US=> NFn3[XZUSU6JRWK=
COLO-320-HSR Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPxTWM2OD1yLkG5OVMzKM7:TR?= M1TUdXNCVkeHUh?=
BT-474 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV32cIR1UUN3ME2wMlIxQDl{IN88US=> Mo\jV2FPT0WU
GDM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PC[WlEPTB;MD6yNVk4OSEQvF2= MoC0V2FPT0WU
NCI-H2196 NFXORVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzQbZl3UUN3ME2wMlIzOjN3IN88US=> NWDDSIlYW0GQR1XS
KP-N-RT-BM-1 NE\IXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPIVWdKSzVyPUCuNlI{PDlizszN MUXTRW5ITVJ?
KNS-81-FD MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPLTWM2OD1yLkKyPVU5KM7:TR?= M1LZeHNCVkeHUh?=
COLO-668 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTITWM2OD1yLkKzOlc2KM7:TR?= MlrJV2FPT0WU
C2BBe1 M4XvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX4fFExUUN3ME2wMlI3PzR5IN88US=> NHL5coZUSU6JRWK=
Ramos-2G6-4C10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHFTWM2OD1yLkK2PVU1KM7:TR?= NGDYNnhUSU6JRWK=
CAS-1 MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHvN3hjUUN3ME2wMlI4ODl4IN88US=> Mn\ZV2FPT0WU
GOTO M4jyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe5Vm1KSzVyPUCuNlc5QTRizszN M2fPVXNCVkeHUh?=
LP-1 NE\6dndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jTRmlEPTB;MD6yPFA2PyEQvF2= NIj3cGVUSU6JRWK=
NCI-SNU-1 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fJS2lEPTB;MD6yPVQzOiEQvF2= NXjBVXEzW0GQR1XS
EB-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPNTWM2OD1yLkK5PVc6KM7:TR?= MVzTRW5ITVJ?
MHH-NB-11 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwM{C0NFIh|ryP NE\OSHVUSU6JRWK=
SK-N-FI M3jnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwM{G2PVIh|ryP MkjiV2FPT0WU
HCC2157 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[yTWM2OD1yLkOzPVE{KM7:TR?= M2nvNnNCVkeHUh?=
SIMA NIfac|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfzbIJ7UUN3ME2wMlM1PThzIN88US=> MVzTRW5ITVJ?
MDA-MB-134-VI MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M172TWlEPTB;MD6zOlkzQCEQvF2= M2P2UnNCVkeHUh?=
NCI-H1694 NHX2T5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DVdWlEPTB;MD6zO{DPxE1? NUPjSnZRW0GQR1XS
EHEB NVvuZm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrPNVlKSzVyPUCuN|kxQDVizszN M{Oye3NCVkeHUh?=
U-266 NXTacXA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrjfpFKSzVyPUCuN|k5PDZizszN NYKwTFFUW0GQR1XS
LC-1F NGPGOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHhTFFKSzVyPUCuOFM4PjVizszN MUnTRW5ITVJ?
SHP-77 NYqzTJlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\rVHVKSzVyPUCuOFc5PTVizszN NUXVUGFtW0GQR1XS
LS-513 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor6TWM2OD1yLkS5N|A4KM7:TR?= Mof5V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 2年-20℃
6月-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
エタノール 18 mg/mL (21.07 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

カスタマーフィードバック (2)


Click to enlarge
Rating
Source , , ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck
Method Confocal Laser Scanning Microscopy Study
Cell Lines HeLa cells
Concentrations 5 μM
Incubation Time 24 h
Results From the figure, it was clear that interestingly α-TOS-Paclitaxel-NP induced highest PARP expression compared to α-TOS-CDDP-NP and α-TOS-Dox-NP.

Click to enlarge
Rating
Source RSC Adv , 2011, 1, 884-892. Paclitaxel purchased from Selleck
Method Microscope image
Cell Lines U937 cells
Concentrations
Incubation Time 24 h
Results The ODS-treated cells in Fig. b looked identical to the untreated cells in Fig. a with a similar rate of natural cell death of less than 3%. When Taxol microcrystals are added to the cell culture (the standard way that Taxol is released into biological systems), decreased cell proliferation rate, pronounced swelling and vacuolization are observed, as shown in Fig. c.

文献中の引用 (14)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ